Long-Term Safety Study of GS-6624 to Treat Idiopathic Pulmonary Fibrosis (IPF)

Inclusion Criteria:

- Previous participation in Phase 1 Gilead clinical trial

- Diagnosis of Idiopathic Pulmonary Fibrosis

- Females of childbearing potential and non-vasectomized males must agree to use highly
effective methods of contraception

- Females must discontinue nursing

- Comply with study requirements

- Have adequate organ function

Exclusion Criteria:

- History or evidence of clinically significant disorder, condition or disease that
would pose a risk or interfere with the study

- Pregnant or lactating

- Clinically significant heart, hepatic or renal disease

- History of cancer within 5 years of screening

- Infection that is not controlled despite antibiotics or other treatment

- History of bleeding diathesis within the last 6 months of Day 1

- Known history of Human Immunodeficiency Virus, hepatitis B or C

- Concern's for subjects compliance

- Other conditions that might put the subject at high risk for treatment complications
or reduce the chance to obtain data required

- Placed on a lung transplant list

- Previous participation in an Idiopathic Pulmonary Fibrosis clinical trial other than
for Gilead Sciences -6624